Treatment of mild to moderate acute sinusitis caused by Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis; mild to moderate chronic bacterial prostatitis caused by Escherichia coli or Proteus mirabilis. Or, for patients receiving hemodialysis, give 200 to 400 mg I. The following organisms have been reported to be susceptible (in vitro) to ciprofloxacin: Campylobacter jejuni, Citrobacterdiversus, Citrobacter freundii, E. For patients receiving hemodialysis or peritoneal dialysis, give 250 to 500 mg P. coli (including enterotoxigenic strains), Enterobacter cloacae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Morganella morganii, P. Antibiotic action: Ciprofloxacin inhibits DNA gyrase, preventing bacterial DNA replication. mirabilis, Proteus vulgaris, Providencia rettgeri, Providencia stuartii, Pseudomonas aeruginosa, Serratia marcescens, Shigella flexneri, Shigella sonnei, Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus faecalis, and Streptococcus pyogenes. To treat overdose, empty the stomach via induced vomiting or lavage. Provide supportive measures and maintain hydration. Peritoneal dialysis or hemodialysis may be helpful, particularly if patient’s renal function is compromised. Duration of therapy depends on type and severity of infection. Background: Little evidence is available to guide the treatment of gram-negative bacteremia. In practice, there are varying degrees of comfort amongst providers with the use of highly bioavailable oral (PO) antibiotics. The purpose of this study was to evaluate the outcome of patients treated with definitive PO ciprofloxacin and those treated with intravenous (IV) antibiotics. Methods: This was a single center retrospective cohort study at Froedtert & the Medical College of Wisconsin for hospitalized patients with at least one positive blood culture for a gram-negative organism between January 2015 and December 2017. Treatment failure was a composite of all-cause mortality and recurrent bacteremia or recurrent primary site infection. Secondary outcomes included 30-day treatment failure, 30- and 90-day all-cause mortality, and 30- and 90-day recurrent infection. Results: Ninety-eight patients in the IV group and 103 patients in the PO group were identified.
The NICE British National Formulary (BNF) and British National Formulary for Children (BNFc) sites are only available to users in the UK, Crown Dependencies and British Overseas Territories. If you believe you are seeing this page in error please contact us. It is very important that your doctor check your or your child's progress while receiving this medicine. This will allow your doctor to see if the medicine is working properly and to decide if you should continue to receive it. Blood and urine tests may be needed to check for unwanted effects. Do not take tizanidine (Zanaflex®) while you are receiving this medicine. Tell your doctor if you or your child are also using theophylline (Theo-Dur®) or other products that contain caffeine (eg, coffee, soda, chocolate). Using these medicines together may increase risks for more serious side effects. Ciprofloxacin may rarely cause inflammation (tendinitis) or tearing of a tendon (the cord that attaches muscles to bones).
Ciprofloxacin injection is used to treat bacterial infections in many different parts of the body. It is also used to treat anthrax infection after inhalational exposure. This medicine is also used to treat and prevent plague (including pneumonic and septicemic plague). Ciprofloxacin belongs to the class of drugs known as quinolone antibiotics. It works by killing bacteria or preventing their growth. However, this medicine will not work for colds, flu, or other virus infections. This medicine is to be given only by or under the direct supervision of your doctor. This includes bone and joint infections, intra abdominal infections, certain type of infectious diarrhea, respiratory tract infections, skin infections, typhoid fever, and urinary tract infections, among others. Ciprofloxacin is used to treat a wide variety of infections, including infections of bones and joints, endocarditis, gastroenteritis, malignant otitis externa, respiratory tract infections, cellulitis, urinary tract infections, prostatitis, anthrax, and chancroid. Ciprofloxacin only treats bacterial infections; it does not treat viral infections such as the common cold. For certain uses including acute sinusitis, lower respiratory tract infections and uncomplicated gonorrhea, ciprofloxacin is not considered a first-line agent. Ciprofloxacin occupies an important role in treatment guidelines issued by major medical societies for the treatment of serious infections, especially those likely to be caused by Gram-negative bacteria, including Pseudomonas aeruginosa. For example, ciprofloxacin in combination with metronidazole is one of several first-line antibiotic regimens recommended by the Infectious Diseases Society of America for the treatment of community-acquired abdominal infections in adults. In other cases, treatment guidelines are more restrictive, recommending in most cases that older, narrower-spectrum drugs be used as first-line therapy for less severe infections to minimize fluoroquinolone-resistance development.
Monographs for Commonly Administered Intravenous Medications in Home. For patients receiving ciprofloxacin IV, first dose should be given in the hospital or. Ciprofloxacin systemic. Adults 500 mg P. O. q 12 hours or 400 mg I. V. q 12 hours. Antibiotic action Ciprofloxacin inhibits DNA gyrase, preventing bacterial.